Mar 11 2019
The National Institutes of Health has announced a new long-term study to improve our understanding of the impacts of early exposure to opioids and other substances, environmental toxins, and social stress during fetal development and early childhood. The HEALthy Brain and Childhood Development (HBCD) Study, lead by the National Institute on Drug Abuse (NIDA), is part of NIH’s HEAL (Helping to End Addiction Long-Term) Initiative. This ambitious research will help us create detailed baseline standards for healthy brain development in early childhood. To learn more, please visit the NIDA website.
Mar 05 2019
Individuals with major depressive disorder who struggle to manage their symptoms despite trying multiple antidepressant treatments over a long period of time may have treatment-resistant depression. The FDA has approved a new drug for this serious condition through the expedited Breakthrough Therapy designation process. Spravato (esketamine) is a nasal spray prescribed to be used together with an oral antidepressant and administered under the supervision of a health care provider. To learn more, please visit the FDA website.
Feb 28 2019
Suicide is the second most common cause of death for people aged 10-24 in the US. Despite this significant and alarming public health issue, there have been very few successful intervention programs for high-risk teens. Encouragingly, a recently-published study shows that when the adults in a high-risk teen’s caregiving environment receive education and support, the risk of death by suicide is reduced by half. For more information about this study, please see this article from Vox.